Unknown

Dataset Information

0

Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.


ABSTRACT: Several pioneering work have established that apart from genetic alterations, epigenetic modifications contribute significantly in tumor progression. Remarkable role of EZH2 in cancer highlights the importance of identifying its targets. Although much emphasis has been placed in recent years in designing drugs and inhibitors targeting EZH2, less effort has been given in exploring its existing targets that will help in understanding the oncogenic role of EZH2 in turn which may provide a more stringent method of targeting EZH2. In the present study, we validated six direct targets of EZH2 that are GPNMB, PMEPA1, CoL5A1, VGLL4, POMT2 and SUMF1 associated with cancer related pathways. Upon EZH2 knockdown, more than two fold increase in the target gene expression was evident. CHIP-qPCR performed in both MCF-7 and MDA-MDA-231 confirmed the in-vivo binding of EZH2 on its identified target. Thirty invasive breast carcinoma cases with their adjacent normal tissues were included in the study. Immunohistochemistry in primary breast tumor tissue array showed tumor dependent expression of EZH2. Array of MERAV expression database revealed the strength of association of EZH2 with its target genes. Real time PCR performed with RNA extracted from breast tumor tissues further authenticated the existing negative correlation between EZH2 and its target genes. Pearson correlation coefficient & statistical significance computed using the matrix provided in the database strengthened the negative correlation between identified target genes and EZH2. KM plotter analysis showed improved relapse-free survival with increased expression of PMEPA1, POMT2, VGLL4 and SUMF1 in breast cancer patients indicating their therapeutic potential. While investigating the relevance of these target genes, different mutations of them were found in breast cancer patients. Seeking the clinical relevance of our study, following our recent publication that reports the role of EZH2 in nicotine-mediated breast cancer development and progression, we observed significant reduced expression of SUMF1 in breast cancer patient samples with smoking history in comparison to never-smoked patient samples.

SUBMITTER: Kumari K 

PROVIDER: S-EPMC6374476 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival.

Kumari Kanchan K   Das Biswajit B   Adhya Amit K AK   Rath Arabinda K AK   Mishra Sandip K SK  

Scientific reports 20190213 1


Several pioneering work have established that apart from genetic alterations, epigenetic modifications contribute significantly in tumor progression. Remarkable role of EZH2 in cancer highlights the importance of identifying its targets. Although much emphasis has been placed in recent years in designing drugs and inhibitors targeting EZH2, less effort has been given in exploring its existing targets that will help in understanding the oncogenic role of EZH2 in turn which may provide a more stri  ...[more]

Similar Datasets

| S-SCDT-EMM-2018-09930 | biostudies-other
| S-EPMC6783652 | biostudies-literature
| S-EPMC9521824 | biostudies-literature
| S-ECPF-GEOD-59198 | biostudies-other
| S-EPMC300882 | biostudies-literature
| S-ECPF-GEOD-40766 | biostudies-other
| S-EPMC3141076 | biostudies-literature
| S-EPMC11003385 | biostudies-literature
| S-EPMC4544543 | biostudies-literature
| S-EPMC6245494 | biostudies-literature